Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.

MLA

Schwarzenberg, Sarah Jane, et al. “Elexacaftor/Tezacaftor/Ivacaftor and Gastrointestinal Outcomes in Cystic Fibrosis: Report of Promise-GI.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, vol. 22, no. 2, Mar. 2023, pp. 282–89. EBSCOhost, https://doi.org/10.1016/j.jcf.2022.10.003.

APA

Schwarzenberg, S. J., Vu, P. T., Skalland, M., Hoffman, L. R., Pope, C., Gelfond, D., Narkewicz, M. R., Nichols, D. P., Heltshe, S. L., Donaldson, S. H., Frederick, C. A., Kelly, A., Pittman, J. E., Ratjen, F., Rosenfeld, M., Sagel, S. D., Solomon, G. M., Stalvey, M. S., Clancy, J. P., … Freedman, S. D. (2023). Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 22(2), 282–289. https://doi.org/10.1016/j.jcf.2022.10.003

Chicago

Schwarzenberg, Sarah Jane, Phuong T Vu, Michelle Skalland, Lucas R Hoffman, Christopher Pope, Daniel Gelfond, Michael R Narkewicz, et al. 2023. “Elexacaftor/Tezacaftor/Ivacaftor and Gastrointestinal Outcomes in Cystic Fibrosis: Report of Promise-GI.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 22 (2): 282–89. doi:10.1016/j.jcf.2022.10.003.